What is the most likely medication used for inhibiting platelet interaction during coronary procedures?

The most likely medication used for inhibiting platelet interaction during coronary procedures is abciximab. This drug is a glycoprotein IIb/IIIa inhibitor, specifically designed to block the final common pathway of platelet aggregation. It works by preventing fibrinogen and other adhesive molecules from binding to activated platelets, thereby reducing platelet aggregation.

In the context of coronary interventions, such as percutaneous coronary interventions (PCI) or angioplasty, abciximab is often used because of its rapid onset and potent effects in preventing thrombosis during these high-risk procedures. The use of abciximab is particularly beneficial in complex cases or when there is a high risk of thrombus formation, such as in patients with unstable angina or those undergoing stenting.

While clopidogrel is also used for antiplatelet management and is important in the long-term prevention of thrombotic events, it works through a different mechanism by irreversibly inhibiting the P2Y12 receptor on platelets. Cilostazol is primarily a vasodilator and is used mainly for managing claudication rather than for acute coronary procedures. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1, reducing